Extracellular vesicles or compositions thereof for use as pharmaceuticals, such as for treating ocular surface diseases

Genetically modified EVs from mesenchymal stromal cells expressing PAX6 and COL7A1 address the limitations of current OSBD treatments by promoting corneal healing and transparency, effectively treating conditions like LSCD and preventing scarring.

JP2024542167APending Publication Date: 2024-11-13フォンダシオン ア ドゥ ロチルド
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527159
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-05
Filing Date
2022-11-04
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current treatments for ocular surface blinding diseases (OSBD) such as corneal ulceration, conjunctivalization, and fibrosis are inadequate, particularly for conditions like corneal epithelial stem cell depletion disease (LSCD), as they either fail to restore the limbal stem cell niche or pose risks like corneal stromal neovascularization and graft rejection.

Method used

The use of extracellular vesicles (EVs) produced from genetically modified mesenchymal stromal cells expressing recombinant PAX6 and/or type VII collagen (rCOL7A1) to promote corneal healing, restore the limbal stem cell niche, and prevent scarring, leveraging their bioactive properties for tissue regeneration and immunomodulation.

Benefits of technology

The EVs effectively restore corneal clarity, promote rapid epithelial healing, prevent scarring, and maintain transparency by enhancing epithelial cell interactions and basement membrane repair, offering a safer and more effective treatment for OSBD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542167000012
    Figure 2024542167000012
  • Figure 2024542167000013
    Figure 2024542167000013
  • Figure 2024542167000001
    Figure 2024542167000001
Patent Text Reader

Abstract

The present invention provides extracellular vesicles (EVs) or compositions thereof for use as a medicament, in particular for use in the treatment or prevention of ocular surface blinding disease (OSBD), said EVs being produced by genetically modified cells comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to extracellular vesicles (EVs) produced by genetically modified cells for use in the treatment or prevention of ocular surface blinding disease (OSBD). [Background technology]

[0002] The ocular surface is composed of the conjunctival and corneal epithelium. These two tissues are adjacent and contiguous, although they exhibit distinct phenotypes. However, the corneal epithelium is transparent, stratified, non-keratinized, and dependent on a transparent, avascular corneal stroma, whereas the conjunctival epithelium is translucent, vascularized, and dependent on an opaque stroma proper.

[0003] The limbus is a specialized structure at the periphery of the cornea that forms the transition between the corneal epithelium and the conjunctival epithelium. The limbus hosts the corneal stem cell niche, which is composed of various cell types, including mesenchymal stromal cells (MSCs) within a specialized extracellular matrix (ECM) and basement membrane, and supports the survival and self-renewal, proliferation, and differentiation of limbal epithelial stem cells (LESCs).

[0004] The properties of both corneal cells and the ECM are important for maintaining corneal transparency. Loss of corneal cells or disruption of the matrix can lead to loss of transparency and impaired vision.

[0005] Maintenance of corneal transparency after wounding depends on the ability of corneal epithelial cells at the wound site to regenerate from the limbus, as well as interactions between epithelial cells and keratinocytes and repair of the epithelial basement membrane (EBM).

[0006] Rapid epithelial healing is crucial to prevent stromal dissolution and / or fibrosis, which may impair visual prognosis. Impaired wound healing with chronic EBM disruption may lead to abnormal epithelial-stromal interactions and massive induction of matrix proteinases, which may cause corneal dissolution and irregular scarring.

[0007] In severe ocular surface blinding diseases (OSBD), inherited or acquired pathologies associated with defective EBM healing can impair corneal epithelial wound healing and cause fibrosis, leading to loss of corneal transparency. Chronic and recurrent ulcers also result from progressive destruction of the stem cell niche (limbus) causing corneal epithelial stem cell deficiency (LSCD). LSCD can result from severe trauma (accidental ocular burns, iatrogenic lesions), chronic inflammation (severe dry eye, mucous membrane pemphigoid, toxic epidermal necrolysis) or congenital diseases (congenital aniridia, recessive dystrophic epidermolysis bullosa). The corneal epithelium gradually undergoes transdifferentiation into a conjunctival or cutaneous phenotype, accompanied by keratinization and loss of overall corneal transparency.

[0008] Although allogeneic corneal transplantation has been successful in restoring vision by replacing the opaque stroma, it is unable to repair the limbal stem cell niche. Therefore, this treatment will fail in patients presenting with LSCD. When LSCD is unilateral, LESCs can be transplanted from the fellow eye prior to corneal transplantation. However, no treatment is available for patients with bilateral LSCD (including genetic causes of LSCD).

[0009] More generally, there is a need for effective methods of treating ocular surface blinding diseases (OSBD), such as conditions associated with corneal ulcers, conditions associated with corneal conjunctivalization, and / or conditions associated with corneal fibrosis.

[0010] Treatments using autologous epithelial cells from other sources have been developed, such as cultured oral mucosal epithelial transplantation (COMET). Although COMET is an attractive concept, it rarely achieves significant and long-term improvement in vision. COMET may also induce stromal neovascularization, which is a major risk factor for corneal graft rejection if performed subsequently [1][2][3].

[0011] Promising cell therapies using MSCs are underway, but have several drawbacks, such as the need for repeated injections or surgery and the lack of control over cell survival and migration.

[0012] Therapeutic methods using extracellular vesicles (EVs) derived from MSCs have also been disclosed for the treatment of corneal scars. EVs derived from MSCs share the bioactive properties of their parent cells and therefore represent a flexible, ready-to-use alternative to stem cell therapies for tissue regeneration, immune modulation or drug delivery, without the risk of allogeneic reactions and with limited side effects.

[0013] WO2019 / 169380 discloses that exosomes derived from corneal MSCs, adipose-derived MSCs, umbilical cord MSCs, or bone marrow-derived MSCs have the ability to reduce scarring in a corneal wound model mouse. One clinical trial using exosomes derived from umbilical cord MSCs to treat ocular surface graft-versus-host disease is ongoing (NCT04213248). Summary of the Invention [Problem to be solved by the invention]

[0014] The present invention provides an improved therapeutic approach for the use of extracellular vesicles (EVs) for the treatment of OSBD. [Means for solving the problem]

[0015] The present invention provides an advanced therapeutic medicine for OSBD patients that combines the advantages of EV therapy and gene therapy using EVs produced from genetically modified cells, particularly those derived from mesenchymal stromal cells.

[0016] In a first aspect, the present invention relates to an extracellular vesicle (EV) or a composition thereof for use as a medicament, said EV being produced by a genetically modified cell comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1), The present invention provides EVs or compositions thereof, wherein the EVs comprise: (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

[0017] In a second aspect, the present invention relates to an extracellular vesicle (EV) or composition thereof for use in the treatment or prevention of ocular surface blinding disease (OSBD), wherein said EV is produced by a genetically modified cell comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1); The present invention provides EVs or compositions thereof, wherein the EVs comprise: (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] definition Unless otherwise specified, all technical terms, designations, and other scientific or scientific terms used herein are intended to have the meaning commonly understood by those of ordinary skill in the art to which this invention belongs. In some cases, terms having a commonly understood meaning are defined herein for clarity and / or ready reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial difference from what is commonly understood in the art.

[0019] The term "extracellular vesicles" or "EVs" refers to lipid-bound vesicles secreted by cells into the extracellular space. The diameter of EVs ranges from a size close to the smallest physically possible unilamellar liposome (approximately 20-30 nanometers) to over 10 microns, but most EVs are less than 200 nanometers. EVs are secreted by various cell types and communicate with other cells through their proteins and nucleic acids. Depending on their cellular origin, EVs have a unique profile of proteins, lipids and polynucleotides that can trigger signaling pathways in other cells or transfer EV products to other cells by fusion of EVs with the cell membrane or endocytosis. EVs can mediate intercellular communication by transferring membrane and cytoplasmic proteins, lipids and nucleic acids between cells. These transferred molecules function in the recipient cells. Three major subtypes of EVs are microvesicles (MVs), exosomes and apoptotic bodies, which are distinguished based on their biogenesis, release pathways, size, contents and functions.

[0020] "PAX6", also known as AN, AN1, AN2, FVH1, MGDA, WAGR, ASGD5 or D11S812E, is a protein encoded by the PAX6 gene in humans. PAX6 is a transcription factor that acts as a key regulator of eye development. PAX6 deficiency is associated with ocular abnormalities such as aniridia. Both corneal epithelial and stromal stem cells express high levels of PAX6 in their limbal stem cell niches [4][5].

[0021] "COL7A1" stands for "type VII collagen alpha 1 chain," also known as EBDCT, EBD1, EBRI, or NDNC8, and is a protein encoded in humans by the COL7A1 gene. It functions as an anchoring fiber between the outer epithelium and the underlying stroma. Mutations in this gene are associated with all forms of dystrophic epidermolysis bullosa. However, in the absence of mutations, an autoimmune response to type VII collagen can result in an acquired form of the disease called epidermolysis bullosa acquisita.

[0022] The term "ocular surface blinding disease" or "OSBD" refers to an ocular surface disease that can lead to blindness. For example, OSBD is known as "severe ocular surface scarring disease" or "OSCD" in the case of conjunctival disease. Thus, in the present invention, OSBD may be substituted for OSCD in the case of conjunctival disease.

[0023] As used herein, the term "culture medium" or "culture medium" refers to any substance or formulation used in the culture of living cells, including components of the environment surrounding the cells. The medium can be any medium suitable for culturing cells. In certain embodiments, the medium is free of serum of any kind, including fetal bovine serum, bovine serum (BS), calf serum (CS), fetal calf serum (PCS), newborn calf serum (NCS), goat serum (GS), horse serum (HS), porcine serum, sheep serum, rabbit serum, rat serum (RS), platelet lysate (such as human platelet lysate).

[0024] The term "pharmaceutical acceptable" means approved by a federal or state government regulatory agency for use in animals and humans, or listed in the United States or European Pharmacopoeia or other generally recognized pharmacopoeias.

[0025] The terms "pharmaceutically acceptable excipient", "pharmaceutically acceptable carrier", "pharmaceutically acceptable diluent" or "pharmaceutically acceptable vehicle" as used interchangeably herein refer to any conventional non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary. Pharmaceutically acceptable carriers are essentially non-toxic to recipients at the dosages and concentrations employed and are compatible with other ingredients of the formulation. Suitable carriers include, but are not limited to, water, glucose, glycerol, saline, ethanol and combinations thereof. Carriers can include additional agents such as wetting agents, emulsifying agents, pH adjusting agents, or auxiliary agents that enhance the effectiveness of the formulation.

[0026] As used herein, the term "pharmaceutical composition" refers to a composition comprising a pharma- ceutical acceptable carrier. For example, a carrier may be a diluent, adjuvant, excipient, or vehicle used when a therapeutic agent is administered. In the context of the present invention, a "pharmaceutical composition" refers to a composition comprising a therapeutically effective amount of EVs and at least one pharma- ceutical acceptable carrier. In some embodiments, a pharmaceutical composition comprises EVs (e.g., isolated EVs) in combination with a non-naturally derived pharma- ceutical acceptable carrier.

[0027] The term "recombinant" is used consistent with its usage in the art to refer to or indicate an organism, cell, protein, or genetic material that has been formed or produced by recombinant means. For example, a recombinant nucleotide sequence (or transgene) is produced by a process involving human intervention and / or is generated from a nucleic acid produced by human intervention (e.g., one or more cycles of replication, amplification, transcription, etc.). For example, a recombinant protein is one that is encoded by a recombinant nucleotide sequence. For example, a recombinant cell is a genetically engineered cell that contains one or more recombinant nucleic acid sequences (or transgenes) that express one or more recombinant proteins.

[0028] As used herein, the terms "subject," "patient," or "individual" refer to a human or non-human mammal (e.g., a rodent (mouse, rat), cat, dog, or primate). Preferably, the subject is a human, male or female.

[0029] Primary and secondary medical uses In a first aspect, the present invention relates to an extracellular vesicle (EV) or a composition thereof for use as a medicament, comprising: The EVs are produced by genetically modified cells comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1); The present invention provides EVs or compositions thereof, wherein the EVs comprise: (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

[0030] In a second aspect, the present invention provides an extracellular vesicle (EV) or a composition thereof for use in the treatment or prevention of ocular surface blinding disease (OSBD), comprising: The EVs are produced by genetically modified cells comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1); The present invention provides EVs or compositions thereof, wherein the EVs comprise: (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

[0031] In some embodiments, the EVs are produced by genetically modified cells that contain a recombinant nucleic acid sequence that expresses rPAX6 isoform A. The amino acid sequence of rPAX6 isoform A is SEQ ID NO: 1. According to these embodiments, the genetically modified cells contain one or more recombinant nucleic acid sequences that express rPAX6 isoform A, such as one or more recombinant nucleic acid sequences of SEQ ID NO: 2.

[0032] In some embodiments, the EVs are produced by recombinant cells that contain a recombinant nucleic acid sequence that expresses rPAX6 isoform B. The amino acid sequence of rPAX6 isoform B is SEQ ID NO: 3. According to these embodiments, the recombinant cells contain one or more recombinant nucleic acid sequences that express rPAX6 isoform B, such as one or more recombinant nucleic acid sequences of SEQ ID NO: 4.

[0033] In some embodiments, the EVs are produced by genetically engineered cells that include a recombinant nucleic acid sequence that expresses rCOL7A1 having the amino acid sequence SEQ ID NO:5. According to these embodiments, the genetically engineered cells include one or more recombinant nucleic acid sequences that express rCOL7A1 of SEQ ID NO:5, such as one or more recombinant nucleic acid sequences of SEQ ID NO:6.

[0034] In some embodiments, the OSBD is a condition associated with a corneal ulcer, a condition associated with corneal conjunctivalization, and / or a condition associated with corneal fibrosis.

[0035] In some embodiments, the condition is corneal epithelial stem cell deficiency (LSCD).

[0036] In some embodiments, the LSCD comprises: Corneal lesions, such as corneal burns (e.g. chemical burns) or physical lesions of the cornea (e.g. limbal scars); Chronic inflammation of the cornea, such as severe dry eye (e.g. Sjögren's syndrome), mucous membrane pemphigoid, or toxic epidermal necrolysis; or Congenital disorders of the cornea, such as congenital aniridia, aniridia-associated keratopathy (AAK) or recessive dystrophic epidermolysis bullosa (RDEB) This results from

[0037] In some other embodiments, the condition is neurotrophic keratitis, recurrent corneal erosion syndrome, or mild dystrophic epidermolysis bullosa.

[0038] In some other embodiments, the condition is ocular GVHD (graft-versus-host disease).

[0039] In some embodiments, the EVs or compositions thereof disclosed herein have the property of repairing the structure of corneal epithelial cells, restoring the interaction between epithelial cells and keratinocytes, and / or repairing the epithelial basement membrane. The EVs or compositions thereof disclosed herein can also promote rapid epithelial healing, promote EBM maturation, and / or strengthen epithelial adhesion to prevent recurrence.

[0040] In some embodiments, the EVs or compositions thereof disclosed herein also prevent corneal opacification and / or improve corneal healing.

[0041] In some embodiments, the EVs or compositions thereof disclosed herein also promote corneal tissue regeneration and / or corneal tissue healing.

[0042] The EVs or compositions thereof disclosed herein can also have one or more of the following properties, but are not limited to: - delaying and / or preventing degeneration of epithelial stem cells; Reduced scarring of corneal wounds, Corneal wound repair, -Treatment and prevention of corneal scarring, -Maintaining corneal transparency, Prevention and treatment of corneal ulcers and erosions, · Prevention and delay of LSCD, Improved epithelial attachment to the basement membrane, - Suppression of referred pain, Prevention of conjunctival fibrosis, including synechiae and fornix shortening; and / or -Prevention of conjunctivalization and keratinization of the ocular surface.

[0043] This represents a groundbreaking treatment innovation for patients with OSBD.

[0044] In some embodiments, the EVs are produced by genetically modified cells (e.g., genetically modified mesenchymal stromal cells) that contain one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6), and the EVs comprise rPAX6 protein and / or rPAX6 mRNA. In these embodiments, the EVs or compositions thereof for use according to the invention are particularly useful for treating corneal damage due to Sjogren's syndrome, congenital aniridia, aniridia-associated keratopathy (AAK), ocular GVHD, Stevens-Johnson-Lyell syndrome, and all other diseases associated with severe dry eye.

[0045] In some embodiments, the EVs are produced by genetically engineered cells (e.g., genetically engineered mesenchymal stromal cells) that contain one or more recombinant nucleic acid sequences that express recombinant collagen VII (rCOL7A1), and the EVs comprise rCOL7A1 protein and / or rCOL7A1 mRNA. In these embodiments, the EVs or compositions thereof for use according to the invention are particularly useful for treating RDEB, recurrent corneal erosion syndrome, and neurotrophic keratitis.

[0046] In some embodiments, the EVs are produced by genetically engineered cells (e.g., genetically engineered mesenchymal stromal cells) that comprise one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and recombinant collagen VII (rCOL7A1), said EVs comprising (i) rPAX6 protein and / or rPAX6 mRNA; and (ii) rCOL7A1 protein and / or rCOL7A1 mRNA. In this embodiment, the EVs or compositions thereof for use according to the invention are particularly useful for the treatment of Sjogren's syndrome, congenital aniridia, aniridia-associated keratopathy (AAK), ocular GVHD, Stevens-Johnson-Lyell syndrome, RDEB, recurrent corneal erosion syndrome, neurotrophic keratitis, and all other diseases associated with severe dry eye.

[0047] The EVs or compositions thereof disclosed herein are delivery vehicles (or cargo) for delivering Col7A1 and / or PAX6 protein / mRNA into cells, tissues or organs, preferably into corneal tissue cells. The EVs or compositions thereof disclosed herein are internalized into cells of a tissue or organ, thereby delivering (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA into cells of a tissue or organ, preferably into corneal tissue cells. Thus, in some embodiments, the EVs are used to treat damage to cells, tissues or organs (e.g., corneal damage) in a patient by administering a therapeutically effective amount of the EVs or compositions thereof to the patient.

[0048] In some embodiments, the EVs comprise a therapeutically effective amount of (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

[0049] According to the present invention, the amount of (i) PAX6 protein and / or PAX6 mRNA (including recombinants and those naturally produced by the cells); and / or (ii) COL7A1 protein and / or COL7A1 mRNA (including recombinants and those naturally produced by the cells) in EVs produced by the genetically modified cells disclosed in the present invention is higher than the amount of (i) PAX6 protein and / or PAX6 mRNA (i.e., those naturally produced by the cells); and / or (ii) COL7A1 protein and / or COL7A1 mRNA (i.e., those naturally produced by the cells) in EVs produced by non-genetically modified cells.

[0050] In some embodiments, the genetically modified cells are induced pluripotent stem cells (iPS).

[0051] In some embodiments, the genetically modified cells are mesenchymal stromal cells (MSCs), such as bone marrow-derived MSCs (BMMSCs), dental pulp MSCs, adipose tissue MSCs, limbal MSCs, placenta MSCs, or umbilical cord MSCs (UCMSCs), preferably UCMSCs. UCMSCs are particularly advantageous due to the innate pro-healing, anti-fibrotic, and anti-inflammatory properties of EVs derived from UCMSCs.

[0052] EVs are produced by genetically modified cells, such as mesenchymal stromal cells (e.g., MSCs). When cells, such as MSCs, are in cell culture, EVs can be secreted into the cell culture medium. EVs can be formed by inward budding of endosomal membranes. EVs may contain one or more polynucleotides or proteins present in the cells that produce the EVs, such as proteins characteristic or specific to MSCs. EVs disclosed herein include (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

[0053] In some embodiments, the loading of rPAX6 and / or rCOL7Al protein and / or mRNA into EVs is increased by modulating shear forces, such as by implementing the "turbulent flow technique" [6]. rPAX6 and / or rCOL7Al protein / mRNA can also be forcibly packaged into EVs by other methods, such as electroporation of exogenous rPAX6 and / or rCOL7Al protein / mRNA [7] or sonication of exogenous rPAX6 and / or rCOL7Al protein / mRNA. Cell nanoporation has also been described to encapsulate selected mRNAs into EVs [8].

[0054] The recombinant cells producing EVs are so-called engineered such that one or more recombinant nucleic acid sequences expressing rPAX6 and / or Col7Al rCOL7Al are under the control of appropriate control sequences for their expression (e.g., promoters, enhancers, etc.). Natural or synthetic 5'-UTRs and / or 3'-UTRs can be added to the recombinant cDNA of COL7A1 and / or PAX6 to enhance the enrichment of rCOL7A1 and / or rPAX6 loaded mRNA in EVs.

[0055] Methods for introducing recombinant nucleotide sequences into cells are known in the art, non-limiting examples include stable transduction methods (e.g., recombinant viral vector-mediated methods, liposomes, microinjection, electroporation, particle bombardment, polyethyleneimine) in which the recombinant nucleotide sequence is integrated into the genome of the cell. Transduction methods such as electroporation and polyethyleneimine are preferably performed using the Sleeping Beauty transposon system. The recombinant nucleotide sequence may be included in a vector, more particularly a plasmid or a viral vector, in terms of being expressed in the cell. In a preferred embodiment, the method for introducing recombinant nucleotide sequences encoding rPAX6 and / or rCOL7Al into cells is a recombinant viral vector-mediated method (e.g., lentivirus), electroporation or polyethyleneimine.

[0056] The cells producing EVs may be immortalized. Thus, in some embodiments, the EVs are produced by an immortalized cell line. The cells can be immortalized using conventional techniques, such as using lentiviral constructs that overexpress the oncogene cMYC, SV40 antigen, or telomerase reverse transcriptase (TERT). Immortalization of cells provides the potential for a steady supply of EVs with defined characteristics, reduced variability in EV production, elimination of donor variability, and a safe technique for the treatment of subjects. Immortalization of cells provides the potential for a steady supply of EVs, reduced variability in EV production, elimination of donor variability, and a safe technique for the treatment of patients.

[0057] EVs can be isolated from the culture medium of cells producing EVs, etc., based on any property of EVs. For example, EVs can be isolated based on molecular weight, size, shape, composition or biological activity. Any suitable technique can be used to isolate EVs, including, for example, centrifugation, filtration, chromatography, size exclusion and / or affinity, preferably tangential flow filtration.

[0058] In some embodiments, the EVs or compositions thereof are administered by ocular and / or subconjunctival injection.

[0059] Compositions containing EVs can be formulated as pharmaceutical compositions in a variety of forms (e.g., ocular injections such as eye drops) adapted to the selected route of administration.

[0060] The pharmaceutical composition can be administered in various ways, such as intraocular administration. The composition can be prepared in water, optionally mixed with a non-toxic surfactant. The pharmaceutical composition can also be prepared in glycerol, liquid polyethylene glycol, triacetin and mixtures thereof, as well as in oils. The pharmaceutical composition can also be prepared in a biological mixture, such as Wharton's jelly. Under normal conditions of storage and use, the pharmaceutical composition can contain a preservative to prevent the growth of microorganisms.

[0061] Pharmaceutical compositions suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders containing EVs suitable for extemporaneous preparation of sterile injectable compositions. In any case, the final dosage form should be sterile, fluid, and stable under the conditions of manufacture and storage. The liquid carrier or vehicle may be a solvent or liquid dispersion medium including water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, non-toxic glyceryl esters, and suitable mixtures thereof.

[0062] Useful liquid carriers include water, alcohols or glycols, or water / alcohol / glycol blends in which the EVs can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as additional antimicrobial agents can be added to optimize properties for a given application.

[0063] The effective dosage and route of administration of the EV or composition thereof of the present invention are conventional. The exact amount of EV (effective dose) will vary from subject to subject, depending, for example, on the species, age, weight, and general or clinical condition of the subject, the severity or mechanism of any disease being treated, the specific agent or vehicle used, the method and schedule of administration, etc. Therapeutically effective doses can be empirically determined by conventional procedures known to those of skill in the art. For example, effective doses can be initially estimated in either cell culture assays or suitable animal models. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine doses and routes useful for administration in humans. Therapeutic doses can also be selected by analogy with the dosages of comparable therapeutic agents.

[0064] The particular mode of administration and dosing regimen will be selected by the attending clinician, taking into account the particulars of the case (e.g., the subject, the disease, the disease state involved, and whether the treatment is prophylactic.) Treatment may involve daily or multiple daily administrations of EV or compositions thereof over a period ranging from several days to several months.

[0065] In a particularly preferred embodiment, the pharmaceutical composition of the present invention is formulated as an ophthalmic preparation for administration to the eye, and thus has formulation elements specifically selected for this purpose. For example, the most widely used ophthalmic buffers are boric acid vehicles and Sorensen's modified phosphate buffer. The boric acid vehicle is a 1.9% solution of boric acid in purified water or preferably sterile water. It is isotonic with tears. It has a pH of about 5, which is useful for extemporaneous formulation of eye drops of drugs that are most stable at acidic pH. In some cases, it is convenient to use a buffer as a osmolality adjuster. In situations where an unbuffered eye drop is desired, a compatible salt or nonelectrolyte approved for ophthalmic products can be used. Sodium chloride, sodium nitrate, sodium sulfate, and glucose are common neutral osmolality adjusters.

[0066] In typical eye drops, preservatives are used to prevent the growth of microorganisms that may be accidentally introduced when the container is opened during use, or to destroy the microorganisms. Benzyl alcohol, thimerosal, and parabens are preservatives commonly found in eye drops.

[0067] Additionally, certain active ingredients may be susceptible to oxidative degradation. Where oxidation is a problem, antioxidants can be included. Sodium metabisulfite and sodium bisulfite are accepted for this purpose in pharmaceutical formulations.

[0068] Finally, increasing the viscosity of an ophthalmic product increases its residence time in the eye, thus extending the time for drug absorption and effectiveness. A number of viscosity enhancing materials can be used, with methylcellulose being a common example.

[0069] In some embodiments, the EVs or compositions thereof disclosed herein are delivered by direct injection into the corneal stroma. In other embodiments, the EVs or compositions thereof are delivered by coating the inner surface of a contact lens with an EV-containing hydrogel and contacting the contact lens with the eye. Such embodiments can employ many of the reagents and / or method steps performed in the treatment of OSBD. [Brief description of the drawings]

[0070] [Figure 1] rPAX6 expression in umbilical cord mesenchymal stromal cells (UC-MSCs). A) UC-MSCs were transduced with (UC-MSC_PAX6) or not with a lentiviral vector allowing stable PAX6 expression.

number

number

number

number

[0071] [Diagram 2]A) Representative examples of nanotracking analysis (NTA) of resuspended pellets after conditioned medium ultracentrifugation performed on EVs from control UC-MSCs (WT, top panel) and EVs from UC-MSCs transduced with COL7A1 retrovirus (COL7A1, bottom panel). NTA profiles were similar, typical of EV profiles. B) COL7A1 mRNA expression in EVs from control UC-MSCs (WT, black bars) and EVs from UC-MSCs transduced with COL7A1 retrovirus (COL7A1, dashed bars) relative to three independent housekeeping genes GAPDH, ACTB, and PPIA. C) Immunostaining for COL7A1 and DAPI staining of HCLE cell line as a positive control showing endogenous COL7A1 expression and BeFa cell line as a negative control without COL7A1 staining. BeFa cells were incubated with UC-MSC control EVs (BeFa+WT EVs) or UC-MSC EVs transduced with COL7A1 retrovirus (BeFa+COL7A1 EVs) at an MOI of 5.106 for 24 h (scale bar 10 μm). D) Immunostaining for COL7A1 and DAPI staining of HCLE cell lines as positive controls showing endogenous COL7A1 expression and BeFa cell lines as negative controls without COL7A1 staining. BeFa cells were incubated with UC-MSC control EVs (BeFa+WT EVs) or UC-MSC EVs transfected with COL7A1 plasmid and selected (BeFa+COL7A1 EVs) at an MOI of 8.105 for 24 h (scale bar 10 μm). EVs derived from UC-MSCs overexpressing COL7A1 were sufficient to increase COL7A1 staining in the BeFa pathological REBD cell model. EXAMPLES

[0072] Example 1: rPAX6 expression in umbilical cord mesenchymal stromal cells (UC-MSCs) 1.1 Cultivation of UC-MSCs MSCs were isolated from UC Wharton's jelly of a single healthy donor using the explant method

[16] . Cells were grown in αMEM (minimum essential medium) containing 10% serum, antibiotics and antimycotics, and 1 ng / ml bFGF (fibroblast growth factor) in an incubator at 37°C and 5% CO2.

[0073] 1.2 Plasmid design and electroporation PAX6 isoform A and PAX6 isoform B were independently introduced into the pFAR4 vector [9]. The pFAR4 vector is a mini-plasmid without an antibiotic resistance marker and was used as a gene vector to deliver the Sleeping Beauty (SB) transposon system. The pFAR4 vector has successfully demonstrated safety and efficiency of gene delivery and is currently used in clinical trials (ACTRN12618001556235). The SB system consists of two inverted terminal repeats (ITRs) surrounding a gene of interest (GOI) and its promoter (CAG). The ITRs were excised from the transposon plasmid and randomly inserted into the genome by the SB transposase encoded in the second pFAR4 plasmid, which allows stable expression in cells.

[0074] After trypsinization, 1.10 6 UC-MSCs were resuspended in 500 μL of serum- and antibiotic-free αMEM. 20 μg of pFAR4 plasmid containing PAX6 isoform A was added to the cell suspension and incubated on ice for 5 min. The mixture was transferred to an electroporation cuvette (4 mm wide). The cuvette was then inserted into a BTX ECM830 electroporation system. One 50 ms pulse of 200 volts was applied. The cells in the cuvette were then incubated for 10 min in a 37°C, 5% CO2 incubator before being seeded into a cell culture flask and the cells were grown as usual. This procedure resulted in a transfection rate of 15% (Figure 1C).

[0075] 1.3 Lentiviral vector design and transduction Nucleic acids encoding PAX6 isoform A and PAX6 isoform B were independently introduced into a lentiviral vector under the control of the EF1α promoter. The EF1α promoter ensures ubiquitous and stable expression of the cassette. UC-MSCs were resuspended in αMEM containing 10% serum and 5-10 μg / ml polybrene. Lentiviral particles encoding PAX6 isoform A were mixed with the cells at an MOI of 25-50. After 48 hours, the medium containing the viral particles was washed and replaced with the medium used for regular UC-MSC culture. With this procedure, more than 80% of the transduced cells can be obtained.

[0076] 1.4 Production of EVs UC-MSCs stably expressing the GOI were grown routinely until the cells reached 80%–90% confluency. The cells were then rinsed three times with starvation medium (αMEM without serum and dFGF). The cells were incubated in starvation medium at 37°C and 5% CO2 for 2 h, the medium was replaced once more, and the cells were incubated for 48 h. Additionally, EV production by the cells can be increased by increasing shear forces using EVerZom's "turbulent flow technology" [6].

[0077] The resulting conditioned medium was centrifuged once at 500G for 5 min, and the supernatant was centrifuged a second time at 1000G for 10 min. The supernatant forming the conditioned medium was collected and stored at -80°C. Assessment of EV content and size distribution in the conditioned medium was assessed by nanoparticle tracking analysis (NTA), and the conditioned medium was stored at -80°C.

[0078] Furthermore, after harvesting the conditioned medium, cell samples were subjected to cytometric analysis to obtain the percentage of cells expressing the GOI, and RNA samples were prepared and analyzed by RT-qPCR to obtain the expression level of the GOI in the entire cell population (Figure 1B).

[0079] 1.5 EV isolation EVs were isolated by tangential flow ultrafiltration (TFF) or ultracentrifugation. First, the conditioned medium was clarified (0.45 filtration) and subjected to TFF. A KFR2i device (Spectrum Laboratories) was used, a hollow fiber filtration system capable of ultrafiltration of sample volumes ranging from 50 mL to 10 L. Filtration was operated at a constant shear rate with continuous feed rate control. Filtration was controlled by a pressure sensor to ensure maximum reproducibility of the process.

[0080] Starting with a 1.1 L solution of conditioned medium, it took approximately 4 h to isolate EVs with an expected yield of 90%. EVs were isolated in starvation medium, which was then replaced with another liquid medium, such as normal saline.

[0081] Ultracentrifugation was performed at 150,000G for 2 hours at 4°C. The medium was discarded and the resulting pellet was resuspended in a small amount of PBS. The extracellular vesicles were stored at -80°C or used directly in experiments.

[0082] 1.6 Analysis of EV content Each batch of EVs is controlled for the content of mRNA and protein of interest by RT-qPCR and ELISA, respectively.

[0083] EV mRNA was extracted from control and modified UC-MSC conditioned medium using the exoRNeasy kit (Qiagen®) according to the manufacturer's recommendations. Reverse transcription was performed using SuperScript TMIII Reverse Transcriptase (Invitrogen®) was used according to the manufacturer's instructions. Quantitative PCR was established using SYBR GREEN detection. qPCR was performed with 40 cycles of amplification. Expression levels were relative to three independent housekeeping genes PPIA, ACTB and GAPDH. Primer pairs used were validated in-house: PAX6 forward ATGAGGCTCAAATGCGACTT (SEQ ID NO:7) and reverse CATTTGGCCCTTCGATTAGA (SEQ ID NO:8); ACTB forward GAAGATCAAGATCATTGCTCCT (SEQ ID NO:11) and reverse TACTCCTGCTTGCTGATCCA (SEQ ID NO:12); PPIA forward CGCGTCTCCTTTGAGCTGTT (SEQ ID NO:13) and reverse ACTTGCCACCAGTGCCATTA (SEQ ID NO:14). GAPDH forward TATCGTGGAAGGACTCATGACCA (SEQ ID NO:15) and reverse GGATGATGTTCTGGAGCCC (SEQ ID NO:16).

[0084] The results are shown in Figure 1D. The PAX6 mRNA content in EV PAX6 relative to ACTB, GAPDH, or PPIA was increased compared to EVs derived from unmodified UC-MSCs.

[0085] 1.7 In vitro analysis of PAX6 transcriptional activity in target cells incubated with EVs produced by UC-MSCs expressing rPAX6 according to the present invention

[0086] To assess PAX6 transcriptional activity, a reporter was constructed. Repeats of the consensus sequence for the PAX6 binding site were inserted before a CMV minimal promoter followed by GFP and luciferase. Activation of the promoter requires PAX6 binding. GFP fluorescence can be quantified by flow cytometry, microscopy or a plate reader, and luminescence by a plate reader, allowing quantitative analysis of PAX6 transcriptional activity in target cells

[10] . The reporter was stably transfected using the Sleeping Beauty transposon system described in Example 1.2 in a skin epithelial cell line that expresses low levels of PAX6 compared to a corneal cell line. Cells carrying the reporter are incubated with EVs derived from UC-MSCs overexpressing PAX6 and EVs derived from unmodified WT UC-MSCs at various MOIs in 96-well plates. After incubation, cells are lysed and assayed with the ONE-Glo® Luciferase Assay System (Promega (R) ) and luciferase activity was determined according to the manufacturer's instructions.

[0087] The results are shown in Figure 1E. The transcriptional activity of PAX6 in skin epithelial cells treated with EVs derived from unmodified UC-MSCs was similar to that in untreated cells, whereas cells treated with EVs derived from PAX6-expressing UC-MSCs showed increased PAX6 transcriptional activity.

[0088] 1.8 In vitro functional rescue of PAX6 haploinsufficiency in corneal cells PAX6 is knocked down on a single allele in an immortalized corneal epithelial cell line by Crispr / cas9

[11] . EVs produced by UC-MSCs expressing rPAX6 according to the present invention are incubated with these cells, and the expression levels of PAX6, KRT3, KRT12 and MMP9 are assessed by RT-qPCR and immunofluorescence

[11]

[12]

[13] to determine transcriptional rescue in haploinsufficient cells. Furthermore, the functionality of the cells is evaluated based on the rescue of cell migration

[11] using the Incucyte® Scratch Wound Assay.

[0089] 1.9 In vitro functional rescue of myofibroblast transformation (inhibition of fibrosis) Immortalized keratocyte cell lines are treated with TGFβ to induce myofibroblast transformation characterized by expression of ACTA2

[14] . Furthermore, primary stromal cells isolated from the human corneoscleral limbus used for endothelial transplantation are also treated with TGFβ to induce myofibroblast transformation. Functional inhibition of the above myofibroblast transformation by EVs produced by UC-MSCs expressing rPAX6 according to the present invention is assessed by the reduction of ACTA2 expression by immunofluorescence and RT-qPCR

[15] .

[0090] 1.10 In vivo functional rescue of Pax6 haploinsufficiency in mice Pax6-deficient mouse model (PAX6 Sey-Neu / + In a study conducted by the National Institute of Integrative Medicine (NII)

[21] , a topical treatment in the form of eye drops containing bioengineered EVs produced by UC-MSCs overexpressing PAX6 according to the present invention is applied to the ocular surface. Rescue of PAX6 expression is assessed by corneal immunostaining for Pax6 and other epithelial markers (e.g., KRT3 and KRT12).

[0091] Example 2: COL7A1 expression in umbilical cord mesenchymal stromal cells (UC-MSCs) 2.1 Cultivation of UC-MSCs The cells were grown under the same conditions as described in Example 1.1.

[0092] 2.2 Plasmid design and electroporation The COL7A1 coding sequence under the control of the EFα promoter was inserted into a vector containing inverted terminal repeats (ITRs) that allow random insertion into the genome by the Sleeping Beauty (SB) transposon system as described in Example 1.2. The vector also contained a neomycin resistance gene. UC-MSCs were transfected by electroporation as described in Example 1.2. 48 hours after transfection, UC-MSCs were treated with 300 μg / ml G418 for at least 1 week.

[0093] 2.3 Lentiviral Vector Design and Transduction Nucleic acid encoding COL7A1 was introduced into a self-inactivating retroviral vector under the control of the EF1α promoter

[17]

[18] . After trypsinization, UC-MSCs were resuspended in αMEM containing 10% serum and 5 μg / ml polybrene. Retroviral particles were mixed with the cells at an MOI of 30. A second transduction was performed under the same conditions after a 24-h interval. After 24 h, the medium containing the viral particles was washed and replaced with medium used for regular UC-MSC culture. Control UC-MSCs underwent the same procedure without the virus.

[0094] 2.4 Production of EVs EVs were produced according to the procedure described in Example 1.4.

[0095] 2.5 EV isolation To extract extracellular vesicles from the conditioned medium, the medium was ultracentrifuged at 150,000G for 2 hours at 4°C. The medium was discarded and the resulting pellet was resuspended in a small amount of PBS. The extracellular vesicles were stored at -80°C or used directly in experiments.

[0096] 2.6 EV quantification The size distribution and concentration of EVs in the conditioned medium and in PBS after ultracentrifugation were assessed by nanoparticle tracking analysis (NTA). Samples were diluted 10- to 200-fold and quantified.

[0097] The results are shown in Figure 2 A. EVs derived from unmodified UC-MSCs and UC-MSCs overexpressing COL7A1 have similar profiles in terms of size distribution.

[0098] 2.7 Analysis of EV mRNA content Analysis of EV RNA content was performed under the same conditions described in Example 1.6. COL7A1 forward GGGAGAGAGTGACCTGCACG (SEQ ID NO:9) and reverse CACCAGCCCTTCGAGAAA (SEQ ID NO:10).

[0099] The results are shown in Figure 2B. EV PAX6, COL7A1 mRNA content relative to ACTB, GAPDH, or PPIA was increased compared to EVs derived from unmodified UC-MSCs.

[0100] 2.8 Collagen VII supplementation assay The BeFa cell line was derived from immortalized RDEB patient keratinocytes homozygous for the COL7A1 exon 3 amino acid 425 (A → G) mutation,

[19] and this cell line shows no measurable COL7A1 protein expression. Cells were grown in DMEM and 30% Nutrient Mixture F-12 Ham, 10% fetal bovine serum, 1% antibiotic-antimycotic, 0.2% triiodothyronine, 0.2% adenine, 0.1% hydrocortisone, 0.2% cholera toxin, 0.1% insulin, and 0.1% EGF. The HCLE cell line (Human Corneal Limbal Epithelial) is an immortalized human corneal epithelial cell line

[20] cultured in Keratinocyte SFM medium (1X) (serum-free) + 20 μg / ml bovine pituitary extract + 0.5 ng / ml recombinant human EGF, 1% antibiotic-antimycotic. This epithelial cell line endogenously expresses type VII collagen.

[0101] UC-MSC control and COL7A1-overexpressing UC-MSC-derived EVs at MOI 8.10 5 ~5.10 6BeFa cells were incubated for 24 h in PBS. Cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with Triton X-100-PBS 0.1% for 5 min, and then incubated in a solution of PBS + 0.05% Triton, 0.05% Tween, and 5% FBS for 30 min. Cells were incubated with mouse anti-collagen VII IgG-1 monoclonal antibody (Clone LH7.2 provided by Sigma-Aldrich®) for 2 h. After rinsing three times with PBS, cells were incubated with anti-mouse IgG secondary antibody and DAPI (4',6-diamidino-2-phenylindole) for 1 h. Images were taken using a confocal microscope (ZEISS®) and analyzed with ImageJ. (R) The results are shown in Figures 2C and 2D. In a cell model lacking COL7A1, treatment with EVs derived from UC-MSCs overexpressing COL7A1 increased COL7A1 staining, whereas treatment with EVs derived from unmodified UC-MSCs showed similar COL7A1 staining compared to untreated cells.

[0102] 2.9 In vitro functional rescue of myofibroblast transformation (inhibition of fibrosis) Immortalized keratocyte cell lines are treated with TGFβ to induce myofibroblast transformation characterized by the expression of ACTA2

[14] . Furthermore, primary stromal cells isolated from the human corneoscleral limbus used for endothelial transplantation are also treated with TGFβ to induce myofibroblast transformation. The functional inhibition of the above myofibroblast transformation by EVs produced by UC-MSCs expressing rCOL7Al according to the present invention is assessed by the reduction of ACTA2 expression by immunofluorescence and RT-qPCR

[15] .

[0103] 2.10 In vivo functional rescue of Col7a1 deficiency in mice A knock-in (KI) mouse model of Col7al deficiency is provided, in which Col7al expression in the basement membrane (skin, esophagus and cornea) is reduced or absent. A topical treatment in the form of eye drops containing bioengineered EVs produced by UC-MSCs overexpressing Col7al according to the present invention is applied to the ocular surface of this mouse model. Rescue of Col7al localization is assessed by immunostaining of the cornea. In addition, corneal inflammation, ulceration, blister formation and wound closure are examined with and without wounding.

[0104] References cited as "[reference number]" [1] Satake et al. Ophthalmology, 118,1524-1530 (2011) [2] Sugiyama et al. The American Society of Gene & Cell Therapy, vol. 22 no. 8 (2014) [3] Hayashida et al. Investigative Ophthalmology & Visual Science, vol. 46, no. 5 (2005) [4] Funderburgh et al. The FASEB Journal (2005) [5] Du et al. Stem Cells, Vol. 23, 1266-1275 (2005) [6] WO / 2019 / 002608 [7] Alvarez-Erviti, L. et al. Nat. Biotechnol. 29, 341-345 (2011) [8] Yang, Z. et al. Nat. Biomed. Eng. 4, 69-83 (2020) [9] Pastor et al. Molecular Therapy: Nucleic Acids c . 11 June (2018)

[10] Oved et al. Biochemical and Biophysical Research Communications, Vol. 582, Pages 100-104 (2021)

[11] Roux et al. Stem Cells, Vol. 36: 1421-1429 (2018)

[12] Latta et al. Exp. Eye Res., Vol. 167, 100-109 (2018)

[13] Sivak et al. Developmental Biology, Vol. 222, Issue 1, 41-54 (2000)

[14] Jesper et al. Investigative Ophthalmology & Visual Science, Vol. 44, 1850-1858 (2003)

[15] Shojaati et al. Stem Cells Transl. Med., Vol. 8, 1192-1201 (2019)

[16] Hassan et ai. Int. J. Stem Cells, Vol. 10, 184-192 (2017)

[17] Jackow et al. J. Invest. Dermatol., Vol. 136, 1346-1354 (2016)

[18] Titeux et al. Mol. Then, Vol. 18, 1509-18 (2010)

[19] Mecklenbeck et al. Hum. Gene Then, Vol. 13, 1655-62 (2002)

[20] Gipson et al. Invest. Ophtalmol. Vis. Sci., Vol. 44, 2496-506 (2003)

[21] Rabiee et al. Sci. Transl. Med., Vol. 12, eaaz4894 (2020)

[0105]

Table 1

Table 2

Table 3

Table 4-1

Table 4-2

Table 4-3

Table 5

Claims

1. An extracellular vesicle (EV) or a composition thereof for use as a medicament, comprising: The EV is produced by a genetically engineered cell comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1); An EV or a composition thereof, wherein the EV comprises: (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

2. 1. An extracellular vesicle (EV) or a composition thereof for use in the treatment or prevention of ocular surface blinding disease (OSBD), comprising: The EV is produced by a genetically engineered cell comprising one or more recombinant nucleic acid sequences expressing recombinant paired box 6 (rPAX6) and / or recombinant type VII collagen (rCOL7A1); An EV or a composition thereof, wherein the EV comprises: (i) rPAX6 protein and / or rPAX6 mRNA; and / or (ii) rCOL7A1 protein and / or rCOL7A1 mRNA.

3. EV or a composition thereof as described in claim 2, wherein the OSBD is a condition associated with corneal ulceration, a condition associated with corneal conjunctivalization, and / or a condition associated with corneal fibrosis.

4. EV or a composition thereof as described in claim 3, wherein the condition is corneal epithelial stem cell deficiency (LSCD).

5. The LSCD is Corneal lesions, such as corneal burns and physical lesions of the cornea; Chronic inflammation of the cornea, such as severe dry eye, mucous membrane pemphigoid, or toxic epidermal necrolysis; or Congenital disorders of the cornea, such as congenital aniridia, aniridia-associated keratopathy (AAK) or recessive dystrophic epidermolysis bullosa (RDEB) 5. The EV or composition thereof of claim 4, which results from

6. EV or a composition thereof according to claim 3, wherein the condition is neurotrophic keratitis, recurrent corneal erosion syndrome or mild dystrophic epidermolysis bullosa.

7. 7. The EV or a composition thereof according to any one of claims 1 to 6, wherein the EV prevents corneal opacification and / or improves corneal healing.

8. The EV or composition thereof described in any one of claims 1 to 6, wherein the EV is produced by an immortalized cell line.

9. The EV or composition thereof according to any one of claims 1 to 6, wherein the cell is an induced pluripotent stem cell (iPS cell) or a mesenchymal stromal cell (MSC), such as a bone marrow-derived MSC (BDMSC) or an umbilical cord MSC (UCMSC).

10. EV or a composition thereof described in any one of claims 1 to 6, wherein the cell is UCMSC.

11. The EV or composition thereof described in any one of claims 1 to 6, wherein the EV or composition thereof is administered to the eye.